Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Long-Term Investments (2021 - 2026)

Oric Pharmaceuticals filings provide 6 years of Long-Term Investments readings, the most recent being $137.8 million for Q1 2026.

  • Quarterly Long-Term Investments rose 587.55% to $137.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $137.8 million through Mar 2026, up 587.55% year-over-year, with the annual reading at $110.8 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments hit $137.8 million in Q1 2026 for Oric Pharmaceuticals, up from $110.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $137.8 million in Q1 2026 and bottomed at $9.6 million in Q2 2023.
  • Average Long-Term Investments over 5 years is $40.6 million, with a median of $22.0 million recorded in 2022.
  • The largest annual shift saw Long-Term Investments plummeted 65.37% in 2024 before it surged 1159.33% in 2025.
  • Oric Pharmaceuticals' Long-Term Investments stood at $22.0 million in 2022, then increased by 22.33% to $26.9 million in 2023, then crashed by 62.77% to $10.0 million in 2024, then skyrocketed by 1007.84% to $110.8 million in 2025, then grew by 24.39% to $137.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Long-Term Investments are $137.8 million (Q1 2026), $110.8 million (Q4 2025), and $125.9 million (Q3 2025).